– Our website is undergoing an update –
The information currently available on the website concerns the previous 2018-2022 labeling.
WHO ARE WE
CARPEM is an Integrated Cancer Research Site (SIRIC) that focuses on the development of new personalized cancer treatments while working on prevention.
SIRICs were set up by the French National Cancer Institute (INCa). The SIRIC label for our CARPEM programme is a recognition of the excellence of our research and clinical teams in cancer research, who have real know-how in translational research. Translational research is essential to bridge the gap between fundamental research (basic mechanisms) and clinical research (medical application).
To achieve our objectives, we have brought together the cancer research strengths of three major hospitals of the Assistance Publique des Hôpitaux de Paris, AP-HP (Georges Pompidou, Cochin and Necker).
CARPEM brings together 350 doctors and researchers dedicated to care and research.
23 RESEARCH TEAMS
11 CLINICAL TEAMS
OUR 3 programs
The objective of this programme is to integrate metabolism in a broad sense, ranging from lifestyle risk factors to molecular mechanisms induced in tumour or immune cells, with the mechanisms of cellular transformation and immune control.
Tumour heterogeneity, a challenge for patient management
This programme involves the comprehensive study of tumour heterogeneity, which plays an important role in treatment resistance and is a limitation to effective precision medicine.
and health democracy
This programme addresses the triple technical, clinical and ethical challenge of massive data production, integration and sharing by encouraging patients and their relatives to become key players in cancer research.
We federate 11 clinical teams from 3 major
hospitals in Paris (HEGP, Cochin and Necker)
a wide range of cancers.
23 research teams in the largest Parisian institutes are dedicated to cancer research.